
Best Practice Tariff: Tranexamic acid why change

Dr Ian Roberts Director, Clinical Trials Unit, LSHTM University of London




TXA reduces surgical bleeding



TXA reduces surgical bleeding

(Ker et al, BJS 2013)



95 trials

72 trials

ORIGINAL ARTICLE

Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery

Paul S. Myles, M.P.H., M.D., Julian A. Smith, F.R.A.C.S., Andrew Forbes, Ph.D., Brendan Silbert, M.B., B.S., Mohandas Jayarajah, M.B., B.S.,
Thomas Painter, M.B., Ch.B., D. James Cooper, M.D., Silvana Marasco, Ph.D., John McNeil, Ph.D., Jean S. Bussières, M.D., Shay McGuinness, M.B., Ch.B., Kelly Byrne, M.B., Ch.B., Matthew T.V. Chan, M.B., B.S., Ph.D., Giovanni Landoni, M.D., and Sophie Wallace, M.P.H., for the ATACAS Investigators of the ANZCA Clinical Trials Network*

ABSTRACT

BACKGROUND


Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes. Furthermore, there are concerns that tranexamic acid may have prothrombotic and proconvulsant effects.

METHODS


In a trial with a 2-by-2 factorial design, we randomly assigned patients who were scheduled to undergo coronary-artery surgery and were at risk for perioperative complications to receive aspirin or placebo and tranexamic acid or placebo. The results of the tranexamic acid comparison are reported here. The primary outcome was a composite of death and thrombotic complications (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after surgery.




TXA reduces death from bleeding in trauma



Death due to bleeding in trauma






TXA within 3 hours of injury fatal or non fatal occlusive events


Thrombotic events#	TXA [n = 6784]	Placebo [n = 6700]	RR (95% CI)	p-value
Any event	98 (1·4%)	141 (2·1%)	0.69 (0.53 – 0.89)	0.004
Any arterial event	47 (0.7%)	81 (1·2%)	0.57 (0.40-0.82)	0.002
Myocardial infarction	23 <i>(</i> 0·3%)	47 (0·7%)	0·48 (0·29 – 0·79)	0.003
Stroke	28 (0·4%)	40 (0·6%)	0·69 (0·42 – 1·12)	0.131
Any venous event	60 (0·9%)	71 (1·1%)	0.83 (0.59–1.17)	0.299
Pulmonary embolism	42 (0·6%)	47 (0·7%)	0·88 (0·58 – 1·34)	0∙555
Deep vein thrombosis	25 <i>(</i> 0·4%)	28 (0·4%)	0·88 (0·51 – 1·51)	0.647



WOMAN Trial Collaborators

Death due to bleeding






Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients

Interpretation Death from bleeding occurs soon after onset and even a short delay in treatment reduces the benefit of tranexamic acid administration. Patients must be treated immediately. Further research is needed to deepen our understanding of the mechanism of action of tranexamic acid.





Early treatment is essential



Effect of treatment delay on the survival benefit from tranexamic acid



YEAR 2016

Median time to TXA treatment = 1.45 hours (0.85 - 2.50)

30% trauma patients received TXA within the first hour





median 49 minutes (33 - 72)

median 111 minutes (77 – 162)



Our ref: POC-1134979

Barry Sheerman MP House of Commons, London. SW1A 0AA

From the Lord O'Shaughnessy Parliamentary Under Secretary of State for Health (Lords)

> 39 Victoria Street London. SWIH OEU

Tel: 020 7210 4850

2 1 JUN 2018

Thank you for your letter dated 31 May 2018 regarding the usages of tranexamic acid (TXA) by paramedics.

As you correctly state, TXA has proven benefits demonstrated by research funded by the National Institute for Health Research. All ten NHS ambulance trusts now carry TXA, with clinical guidance provided by the Joint Royal College Ambulance Liaison Committee, and local guidelines and protocols in place for ambulances and acute hospital trusts.

You also mention the Best Practice Tariff (BPT) for trauma in your letter. I can confirm that in alignment with recent research findings, NHS Improvement is currently engaging on proposals to change the Major Trauma Care BPT guidance in the next tariff to cover administration of tranexamic acid within one hour of injury for patients receiving blood products. The Department of Health and Social Care continues to ensure that practice in the NHS is informed by research evidence.

I hope this reply is helpful.


JAMES O'SHAUGHNESSY

Best practice tariff for trauma:

Incentive payment if "TXA given within 3 hours if patient receives blood within 6 hours.

in alignment with recent research..


"TXA within one hour for patients receiving blood products."



TXA: Same benefit regardless of baseline risk

Most trauma patients have a low baseline risk

We need to treat all trauma patients



Tranexamic acid

Safely prevents bleeding

Give it early to all patients at risk

Not about massive transfusion

Not about trauma inducted coagulopathy